Abstract
Vaccines have been described as “weapons of mass protection”. The eradication of many diseases is testament to their utility and effectiveness. Nevertheless, many vaccine preventable diseases remain prevalent because of political and economic barriers. Additionally, the effects of immaturity and old age, therapies that incapacitate the adaptive immune system and the multitude of strategies evolved by pathogens to evade immediate or sustained recognition by the mammalian immune system are barriers to the effectiveness of existing vaccines or development of new vaccines. In the front line of defence against the pervasiness of infection are the elements of the innate immune system. Innate immunity is under studied and poorly appreciated. However, in the first days after entry of a pathogen into the body, our entire protective response is dependant upon the various elements of our innate immune repertoire. In spite of its place as our initial defence against infection, attention is only now turning to strategies which enhance or supplement innate immunity. This review examines the need for and potential of innate immune therapies.
Keywords: innate immunity, mannose binding lectin, infection
Current Drug Targets
Title: Alternatives to Conventional Vaccines - Mediators of Innate Immunity
Volume: 5 Issue: 1
Author(s): D. P. Eisen, H. G. Liley and R. M. Minchinton
Affiliation:
Keywords: innate immunity, mannose binding lectin, infection
Abstract: Vaccines have been described as “weapons of mass protection”. The eradication of many diseases is testament to their utility and effectiveness. Nevertheless, many vaccine preventable diseases remain prevalent because of political and economic barriers. Additionally, the effects of immaturity and old age, therapies that incapacitate the adaptive immune system and the multitude of strategies evolved by pathogens to evade immediate or sustained recognition by the mammalian immune system are barriers to the effectiveness of existing vaccines or development of new vaccines. In the front line of defence against the pervasiness of infection are the elements of the innate immune system. Innate immunity is under studied and poorly appreciated. However, in the first days after entry of a pathogen into the body, our entire protective response is dependant upon the various elements of our innate immune repertoire. In spite of its place as our initial defence against infection, attention is only now turning to strategies which enhance or supplement innate immunity. This review examines the need for and potential of innate immune therapies.
Export Options
About this article
Cite this article as:
Eisen P. D., Liley G. H. and Minchinton M. R., Alternatives to Conventional Vaccines - Mediators of Innate Immunity, Current Drug Targets 2004; 5 (1) . https://dx.doi.org/10.2174/1389450043490703
DOI https://dx.doi.org/10.2174/1389450043490703 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Adeno-Associated Virus-Mediated Gene Transfer in Hematopoietic Stem/Progenitor Cells as a Therapeutic Tool
Current Gene Therapy Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Male Fertility-Implications of Anticancer Treatment and Strategies to Mitigate Gonadotoxicity
Anti-Cancer Agents in Medicinal Chemistry The Chemistry and Bio-Medicinal Significance of Pyrimidines & Condensed Pyrimidines
Current Topics in Medicinal Chemistry Theoretical Analysis for the Safe Form and Dosage of Amygdalin Product
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Mechanisms of Tumor Cell Necrosis
Current Pharmaceutical Design Sources of β-Cells for Cell Therapy in Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The 18 kDa Translocator Protein (TSPO): A New Perspective in Mitochondrial Biology
Current Molecular Medicine Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines
Current Medicinal Chemistry Novel Targets for Apoptosis Modulation: BAG3 Protein and Other Co- Chaperones
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals